Engineered immune cells take on Post-Transplant virus
NCT ID NCT07368634
First seen Jan 31, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study tests a new treatment for Epstein-Barr virus (EBV) infection that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to target and clear the virus. About 18 adults who have EBV in their blood despite standard care will receive infusions of these cells. The goal is to see if the treatment is safe and can eliminate the virus, reducing the risk of serious complications like lymphoproliferative disorder.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.